Journal
CANCER CELL
Volume 38, Issue 6, Pages 788-802Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2020.08.004
Keywords
-
Categories
Funding
- NIH [P30 CA016520, P01 CA210944, R01 CA229803]
- Parker Institute for Cancer Immunotherapy
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression from the earliest stages of tumor inception to subvert adaptive T cell immunity. Single-agent immune modulators have thus far proven clinically ineffective, and multi-modal therapies targeting mechanisms of immunotherapy resistance are likely needed. Here, we review novel immunotherapy strategies currently under investigation to (1) confer antigen specificity, (2) enhance T cell effector function, and (3) neutralize immunosuppressive elements within the tumor microenvironment that may be rationally combined to untangle the web of immune resistance in PDA and other tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available